Key result
Amlodipine plus olmesartan medoxomil combination therapy provided greater reductions in blood pressure and higher goal achievement rates than component monotherapies across difficult-to-treat subgroups including elderly, Black, diabetic, and obese patients.
Why the study?
Does the combination of amlodipine and olmesartan medoxomil improve blood pressure reduction in patients with difficult-to-treat hypertension compared to monotherapy or placebo?
RCT (n=1,940)
Double-blind
Factorial design
Yes
Does the combination of amlodipine and olmesartan medoxomil improve blood pressure reduction in patients with difficult-to-treat hypertension compared to monotherapy or placebo?
p-value: p=<0.025
The combination of amlodipine and olmesartan medoxomil provides a safe and effective option for blood pressure reduction in challenging hypertensive patient populations.
No takes yet. Share an insight, caveat, or question.
Supports amlodipine-olmesartan combination for difficult-to-treat hypertension; confirms greater efficacy than monotherapies across subgroups in this RCT.
Chrysant et al. (2010) conducted an RCT in Hypertension (n=1,940). Amlodipine plus olmesartan medoxomil vs. Amlodipine monotherapy, olmesartan medoxomil monotherapy, and placebo was evaluated on Change from baseline in mean seated diastolic blood pressure (SeDBP) at week 8 (p=<0.025). Amlodipine plus olmesartan medoxomil combination therapy provided greater reductions in blood pressure and higher goal achievement rates than component monotherapies across difficult-to-treat subgroups including elderly, Black, diabetic, and obese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: